Shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) have been given a consensus rating of "Buy" by the six analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock in the last year is $90.20.
A number of equities analysts have commented on the company. StockNews.com upgraded LivaNova from a "hold" rating to a "buy" rating in a research note on Friday, September 9th. Needham & Company LLC reduced their target price on LivaNova from $106.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, August 4th. Finally, The Goldman Sachs Group reduced their target price on LivaNova from $85.00 to $73.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get
LivaNova alerts:
LivaNova Price Performance
LivaNova stock opened at $50.89 on Friday. The stock's fifty day moving average price is $60.41 and its two-hundred day moving average price is $67.56. LivaNova has a one year low of $50.70 and a one year high of $93.89. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.93 and a quick ratio of 2.47. The firm has a market cap of $2.72 billion, a PE ratio of -90.88 and a beta of 0.91.
LivaNova (NASDAQ:LIVN – Get Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.02. LivaNova had a positive return on equity of 9.35% and a negative net
margin of 2.74%. The firm had revenue of $254.20 million for the quarter, compared to analyst estimates of $249.55 million. During the same quarter last year, the company earned $0.52 EPS. The company's revenue was down 3.9% on a year-over-year basis. As a group, research analysts expect that LivaNova will post 1.91 EPS for the current fiscal year.
Institutional Investors Weigh In On LivaNova
Several hedge funds have recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in LivaNova during the 1st quarter worth about $64,579,000. P2 Capital Partners LLC acquired a new position in LivaNova during the 4th quarter worth about $56,968,000. Sachem Head Capital Management LP lifted its holdings in LivaNova by 54.2% during the 4th quarter. Sachem Head Capital Management LP now owns 1,734,500 shares of the company's stock worth $151,647,000 after buying an additional 609,500 shares during the period. Loomis Sayles & Co. L P lifted its holdings in LivaNova by 601.5% during the 2nd quarter. Loomis Sayles & Co. L P now owns 601,679 shares of the company's stock worth $37,587,000 after buying an additional 515,914 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in LivaNova by 63.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 993,066 shares of the company's stock worth $81,263,000 after buying an additional 383,973 shares during the period. Institutional investors and hedge funds own 98.89% of the company's stock.
About LivaNova
(Get Rating)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Read More
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
